Suvorexant

Generic Name: Suvorexant

Brand Names: Belsomra

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₃ClN_₆O_₂

CAS Number: 1030377-33-3

Unique Ingredient Identifier: 081L192FO9

Background: Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

Indication: Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Associated Conditions: Insomnia

Associated Therapies: -

Clinical Trials

Suvorexant for Treatment of AUD and PTSD

Phase 2

Not yet recruiting

Conditions: Alcohol Use Disorder (AUD)
Post Traumatic Stress Disorder (PTSD)
Insomnia

Interventions: Other: Placebo
Drug: Suvorexant

First Posted Date: 2024-11-07

Last Posted Date: 2024-11-12

Lead Sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance

Target Recruit Count: 76

Registration Number: NCT06679062

Locations: 🇺🇸
University of California - Los Angeles, Los Angeles, California, United States
🇺🇸
The University of Texas Health Science Center - Houston, Houston, Texas, United States

A Study of Suvorexant (MK-4305) for the Treatment of Insomnia in Participants With Opioid Use Disorder (MK-4305-098)

Phase 3

Not yet recruiting

Conditions: Insomnia

Interventions: Drug: Suvorexant
Drug: Placebo

First Posted Date: 2024-10-24

Last Posted Date: 2024-10-24

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 300

Registration Number: NCT06655883

Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms

Phase 1

Recruiting

Conditions: Alcohol Use Disorder (AUD)
Healthy Volunteers

Interventions: Drug: Suvorexant
Drug: Placebo

First Posted Date: 2024-07-03

Last Posted Date: 2024-12-05

Lead Sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Target Recruit Count: 150

Registration Number: NCT06484075

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Suvorexant and Alcohol

Early Phase 1

Recruiting

Conditions: Alcohol Use Disorder

Interventions: Drug: Alcohol
Drug: Placebo
Drug: Suvorexant

First Posted Date: 2024-03-22

Last Posted Date: 2024-12-12

Lead Sponsor: University of Kentucky

Target Recruit Count: 30

Registration Number: NCT06326684

Locations: 🇺🇸
Psychopharmacology of Addiction Laboratory, Lexington, Kentucky, United States

Efficacy of Suvorexant on Post-operative Sleep Disturbance

Phase 4

Recruiting

Conditions: Postoperative Insomnia
Postoperative Delirium

Interventions: Drug: Placebo
Drug: Suvorexant

First Posted Date: 2023-04-21

Last Posted Date: 2024-05-22

Lead Sponsor: Columbia University

Target Recruit Count: 92

Registration Number: NCT05823844

Locations: 🇺🇸
NewYork-Presbyterian Allen Hospital/CUMC Milstein Hospital Building, New York, New York, United States

Orexin Receptor Antagonists as Modulators of Threat Sensitivity in Individuals With Alcohol Use Disorder

Early Phase 1

Active, not recruiting

Conditions: Alcohol Use Disorder

Interventions: Other: Placebo
Drug: Suvorexant

First Posted Date: 2022-12-19

Last Posted Date: 2024-06-28

Lead Sponsor: Ohio State University

Target Recruit Count: 71

Registration Number: NCT05656534

Locations: 🇺🇸
The Ohio State University, Columbus, Ohio, United States

Orexin s Role in the Neurobiology of Substance Use Disorder

Not Applicable

Recruiting

Conditions: Nicotine Dependence

Interventions: Drug: Belsomra
Drug: Placebo
Drug: Methylphenidate

First Posted Date: 2022-11-30

Last Posted Date: 2024-10-18

Lead Sponsor: National Institute on Drug Abuse (NIDA)

Target Recruit Count: 140

Registration Number: NCT05630781

Locations: 🇺🇸
National Institute on Drug Abuse, Baltimore, Maryland, United States

Efficacy of Suvorexant in the Treatment of Insomnia in Midlife Women With Pre-Diabetes

Phase 4

Recruiting

Conditions: Insomnia
Diabetes
Menopause

Interventions: Drug: Placebo
Drug: Suvorexant

First Posted Date: 2022-10-25

Last Posted Date: 2023-02-21

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 61

Registration Number: NCT05593653

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Trial of Suvorexant for Sleep in Children With Autism

Phase 2

Recruiting

Conditions: Autism
Autism Spectrum Disorder

Interventions: Drug: Suvorexant
Drug: Placebo

First Posted Date: 2022-09-21

Last Posted Date: 2024-12-16

Lead Sponsor: Stanford University

Target Recruit Count: 26

Registration Number: NCT05546554

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl

Phase 2

Recruiting

Conditions: Placebo
Suvorexant
Opioid Use Disorder

Interventions: Drug: Suvorexant
Drug: Placebo

First Posted Date: 2021-12-06

Last Posted Date: 2024-08-19

Lead Sponsor: Johns Hopkins University

Target Recruit Count: 120

Registration Number: NCT05145764

Locations: 🇺🇸
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy